巨细胞动脉炎患者的快速糖皮质激素减量方案:一项单中心队列研究
在巴塞尔大学医院纳入47例新诊断巨细胞动脉炎患者,采用计划26周糖皮质激素减量方案。32例(68%)复发,多为轻微复发,12个月累积激素剂量为4164 mg,低于已发表数据。
要点
- 47例患者中32例(68%)复发,其中28/32为轻微复发,19/32仅为炎症标志物孤立升高。
- 12个月累积糖皮质激素剂量中位数为4164 mg,低于已发表队列数据。
- 9/47例在中位35周后停用糖皮质激素,且1年内未复发。
核心结论
- 快速糖皮质激素减量方案治疗后,32%的患者在1年时保持无复发,19%停用糖皮质激素。
- 大多数复发为轻微复发,可通过临时增加糖皮质激素剂量处理。
- 12个月累积糖皮质激素剂量远低于已发表队列,通过降低累积剂量进一步减少巨细胞动脉炎患者治疗相关损害似乎是可能的。
研究设计与样本
- 单中心队列研究,纳入巴塞尔大学医院新诊断且仅用糖皮质激素治疗的巨细胞动脉炎患者,采用计划26周糖皮质激素减量方案。
- 从患者记录中收集复发、累积类固醇剂量和治疗相关不良事件数据,共47例患者(64%女性,中位年龄72岁)。
主要发现
- 47例中32例(68%)复发,其中28/32为轻微复发,19/32为炎症标志物孤立升高。
- 严重复发中1例导致永久性视力丧失。
- 复发中位时间为99天(IQR 71-127),复发时糖皮质激素剂量中位数为8 mg(IQR 5-16)。
- 9/47例在中位35周后停用糖皮质激素,且1年内未复发。
- 12个月累积糖皮质激素剂量中位数为4164 mg,低于已发表数据;40%患者发生糖皮质激素相关不良事件,最常见为新发或加重的高血压(19%)、糖尿病(11%)和严重感染(11%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We evaluated the feasibility of a rapid glucocorticoid tapering regimen to reduce glucocorticoid exposure in patients with giant cell arteritis (GCA) treated with glucocorticoids only. METHODS: Newly diagnosed patients with GCA treated with a planned 26-week glucocorticoid tapering regimen at the University Hospital Basel were included. Data on relapses, cumulative steroid doses (CSD) and therapy-related adverse effects were collected from patients' records. RESULTS: Of 47 patients (64% women, median age 72 years), 32 patients (68%) had relapsed. Most relapses were minor (28/32) and 2/3 of those were isolated increased inflammatory markers (19/32). Among major relapses, one resulted in permanent vision loss. The median time until relapse was 99 days (IQR 71-127) and median glucocorticoid dose at relapse was 8 mg (IQR 5-16). Nine of 47 patients stopped glucocorticoids after a median duration of 35 weeks and did not relapse within 1 year. Median CSD at 12 months was 4164 mg which is lower compared with published data. Glucocorticoid-associated adverse effects occurred in 40% of patients, most frequently were new onset or worsening hypertension (19%), diabetes (11%) and severe infections (11%). CONCLUSION: We could demonstrate that 32% of patients remained relapse-free and 19% off glucocorticoids at 1 year after treatment with a rapid glucocorticoid tapering regimen. Most relapses were minor and could be handled with temporarily increased glucocorticoid doses. Consequently, the CSD at 12 months was much lower than reported in published cohorts. Thus, further reducing treatment-associated damage in patients with GCA by decreasing CSD seems to be possible.
引用
- Mensch N, Hemmig AK, Aschwanden M, et al. Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study. RMD Open. 2023. PMID: 37460275. doi:10.1136/rmdopen-2023-003301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。